University of Ottawa Heart Institute, Division of Cardiology, Department of Medicine, University of Ottawa, Ottawa, CANADA K1Y4W7.
Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada, K1H8M5.
Theranostics. 2024 Jan 1;14(2):608-621. doi: 10.7150/thno.89520. eCollection 2024.
Extracellular vesicles (EVs) from human explant-derived cells injected directly into the atria wall muscle at the time of open chest surgery reduce atrial fibrosis, atrial inflammation, and atrial fibrillation (AF) in a rat model of sterile pericarditis. Albeit a promising solution to prevent postoperative AF, the mechanism(s) underlying this effect are unknown and it is not clear if this benefit is dependent on EV dose. To determine the dose-efficacy relationship of EVs from human explant-derived cells in a rat model of sterile pericarditis. Increasing doses of EVs (10, 10, 10 or 10) or vehicle control were injected into the atria of middle-age male Sprague-Dawley rats at the time of talc application. A sham control group was included to demonstrate background inducibility. Three days after surgery, all rats underwent invasive electrophysiological testing prior to sacrifice. Pericarditis increased the likelihood of inducing AF (p<0.05 vs. sham). All doses decreased the probability of inducing AF with maximal effects seen after treatment with the highest dose (10, p<0.05 vs. vehicle). Pericarditis increased atrial fibrosis while EV treatment limited the effect of pericarditis on atrial fibrosis with maximal effects seen after treatment with 10 or 10 EVs. Increasing EV dose was associated with progressive decreases in pro-inflammatory cytokine content, inflammatory cell infiltration, and oxidative stress. EVs decreased NLRP3 (NACHT, LRR, and PYD domains-containing protein-3) inflammasome activation though a direct effect on resident atrial fibroblasts and macrophages. This suppressive effect was exclusive to EVs produced by heart-derived cells as application of EVs from bone marrow or umbilical cords did not alter NLRP3 activity. Intramyocardial injection of incremental doses of EVs at the time of open chest surgery led to progressive reductions in atrial fibrosis and inflammatory markers. These effects combined to render atria resistant to the pro-arrhythmic effects of pericarditis which is mechanistically related to suppression of the NLRP3 inflammasome.
直接注射到开胸手术时心房壁肌肉中的源自人原代细胞的细胞外囊泡 (EVs) 可减少无菌性心包炎大鼠模型中的心房纤维化、心房炎症和心房颤动 (AF)。尽管这是一种预防术后 AF 的有前途的方法,但这种效果的机制尚不清楚,也不清楚这种益处是否依赖于 EV 剂量。为了确定无菌性心包炎大鼠模型中源自人原代细胞的 EV 的剂量-疗效关系。在滑石粉应用时,将递增剂量的 EV(10、10、10 或 10)或载体对照物注射到中年雄性 Sprague-Dawley 大鼠的心房中。包括假手术对照组以证明背景诱导能力。手术后 3 天,所有大鼠在牺牲前进行侵入性电生理测试。心包炎增加了诱导 AF 的可能性(p<0.05 与假手术相比)。所有剂量均降低了诱导 AF 的可能性,最高剂量(10 治疗组效果最大,p<0.05 与载体相比)。心包炎增加了心房纤维化,而 EV 治疗则限制了心包炎对心房纤维化的影响,最高剂量 10 或 10 EV 治疗组效果最大。增加 EV 剂量与促炎细胞因子含量、炎症细胞浸润和氧化应激的逐渐降低相关。EV 通过对驻留的心房成纤维细胞和巨噬细胞的直接作用降低 NLRP3(NACHT、LRR 和 PYD 结构域包含蛋白-3)炎症小体的激活。这种抑制作用是 EVs 特有的,因为心脏来源的细胞产生的 EVs 的应用不会改变 NLRP3 活性。开胸手术时心肌内注射递增剂量的 EVs 可导致心房纤维化和炎症标志物的逐渐减少。这些作用结合起来使心房对心包炎的致心律失常作用具有抗性,这与 NLRP3 炎症小体的抑制有关。